Loading…
PALI
Palisade Bio Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 696389402
$1.41-8.44%Price as of Oct 17, 12:04 UTC · updated once a day, after the close
At a glance
Palisade Bio Inc (PALI) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Denver, United States and has 14 employees. The company is worth $245.72M and trades at 2.4x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $0 in fiscal 2025. It reported a net loss of $16.78M. The share price is 50.7% below its 52-week high of $2.86. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Steve Cohen (Point72 Asset Management), at $10.98M. In that quarter, 2 of them opened or added to the position and 1 reduced it. Over the last 30 days, company insiders bought $28.8K of its stock on the open market and sold none.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $245.72M
- P/E
- 2.4x
- Forward P/E
- —
- P/B
- 2.0x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- $0.60
- ROE
- -51.37%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.62
- 52-week high
- $2.86
- 52-week low
- $1.32
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.9% over 5Y.
today you would have $0.69▼ -99.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 17 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.35 | $1.65 | $8.85 | $78.00 | $975.00 | $3,960.00 | $4,455.00 | $27,900.00 | $154,800.00 | $315,900.00 | $1,205,100.00 | $3,182,400.00 | $3,404,700.00 | $1,275,300.00 | $1,134,900.00 | $2,480,400.00 | $2,094,300.00 | |
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$3.08
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| QSIQuantum-Si Inc | $1.12 | — | 1.4x | 0.00% | -49.11% | $245.15M |
| AMRNAmarin Corp Plc\uk | $11.60 | — | 0.5x | 0.00% | -5.97% | $245.02M |
| IMRXImmuneering Corp | $3.81 | — | 1.3x | 0.00% | -52.15% | $246.5M |
| VNDAVanda Pharmaceuticals Inc. | $4.05 |
About the company
- 14
- Denver, United States